QQQ   359.56 (+0.48%)
AAPL   174.41 (+0.28%)
MSFT   319.07 (-0.14%)
META   304.27 (+2.89%)
GOOGL   130.65 (+0.16%)
AMZN   131.45 (+1.64%)
TSLA   253.75 (-0.76%)
NVDA   418.35 (+1.99%)
NIO   8.60 (+1.78%)
BABA   87.56 (+4.10%)
AMD   96.84 (+0.76%)
T   15.08 (-1.50%)
F   12.51 (+2.54%)
MU   68.62 (+1.06%)
CGC   0.78 (+1.68%)
GE   112.86 (-0.12%)
DIS   82.70 (-0.04%)
AMC   7.75 (+0.65%)
PFE   32.62 (-0.70%)
PYPL   58.53 (-0.15%)
NFLX   382.51 (-0.43%)
QQQ   359.56 (+0.48%)
AAPL   174.41 (+0.28%)
MSFT   319.07 (-0.14%)
META   304.27 (+2.89%)
GOOGL   130.65 (+0.16%)
AMZN   131.45 (+1.64%)
TSLA   253.75 (-0.76%)
NVDA   418.35 (+1.99%)
NIO   8.60 (+1.78%)
BABA   87.56 (+4.10%)
AMD   96.84 (+0.76%)
T   15.08 (-1.50%)
F   12.51 (+2.54%)
MU   68.62 (+1.06%)
CGC   0.78 (+1.68%)
GE   112.86 (-0.12%)
DIS   82.70 (-0.04%)
AMC   7.75 (+0.65%)
PFE   32.62 (-0.70%)
PYPL   58.53 (-0.15%)
NFLX   382.51 (-0.43%)
QQQ   359.56 (+0.48%)
AAPL   174.41 (+0.28%)
MSFT   319.07 (-0.14%)
META   304.27 (+2.89%)
GOOGL   130.65 (+0.16%)
AMZN   131.45 (+1.64%)
TSLA   253.75 (-0.76%)
NVDA   418.35 (+1.99%)
NIO   8.60 (+1.78%)
BABA   87.56 (+4.10%)
AMD   96.84 (+0.76%)
T   15.08 (-1.50%)
F   12.51 (+2.54%)
MU   68.62 (+1.06%)
CGC   0.78 (+1.68%)
GE   112.86 (-0.12%)
DIS   82.70 (-0.04%)
AMC   7.75 (+0.65%)
PFE   32.62 (-0.70%)
PYPL   58.53 (-0.15%)
NFLX   382.51 (-0.43%)
QQQ   359.56 (+0.48%)
AAPL   174.41 (+0.28%)
MSFT   319.07 (-0.14%)
META   304.27 (+2.89%)
GOOGL   130.65 (+0.16%)
AMZN   131.45 (+1.64%)
TSLA   253.75 (-0.76%)
NVDA   418.35 (+1.99%)
NIO   8.60 (+1.78%)
BABA   87.56 (+4.10%)
AMD   96.84 (+0.76%)
T   15.08 (-1.50%)
F   12.51 (+2.54%)
MU   68.62 (+1.06%)
CGC   0.78 (+1.68%)
GE   112.86 (-0.12%)
DIS   82.70 (-0.04%)
AMC   7.75 (+0.65%)
PFE   32.62 (-0.70%)
PYPL   58.53 (-0.15%)
NFLX   382.51 (-0.43%)
NASDAQ:PRAX

Praxis Precision Medicines (PRAX) Stock Forecast, Price & News

$1.46
-0.03 (-2.01%)
(As of 09:52 AM ET)
Compare
Today's Range
$1.45
$1.52
50-Day Range
$0.87
$1.57
52-Week Range
$0.79
$5.25
Volume
10,229 shs
Average Volume
1.36 million shs
Market Capitalization
$187.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Praxis Precision Medicines MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
470.5% Upside
$8.50 Price Target
Short Interest
Healthy
2.12% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Praxis Precision Medicines in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$10,600 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.77) to ($1.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

393rd out of 965 stocks

Pharmaceutical Preparations Industry

172nd out of 453 stocks


PRAX stock logo

About Praxis Precision Medicines (NASDAQ:PRAX) Stock

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.

PRAX Price History

PRAX Stock News Headlines

Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
What 5 Analyst Ratings Have To Say About Praxis Precision Medicine
H.C. Wainwright Remains a Buy on Praxis Precision Medicines (PRAX)
See More Headlines
Receive PRAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter.

PRAX Company Calendar

Last Earnings
8/09/2023
Today
9/21/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRAX
Fax
N/A
Employees
109
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.50
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+470.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-214,030,000.00
Pretax Margin
-10,716.19%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.62 per share

Miscellaneous

Free Float
122,242,000
Market Cap
$191.52 million
Optionable
Not Optionable
Beta
2.93
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Marcio Souza M.B.A.Mr. Marcio Souza M.B.A. (Age 44)
    Pres, CEO & Director
    Comp: $1.04M
  • Mr. Timothy Edwin Kelly (Age 49)
    CFO & Treasurer
    Comp: $633.49k
  • Dr. Steven Petrou B.Sc. (Hons.)
    Ph.D., Co-Founder & Chief Scientific Officer
  • Lauren Mastrocola
    VP of Fin. & Principal Accounting Officer
  • Dr. Karl Hansen Ph.D.
    Chief Technical Operations Officer
  • Alex Kane
    VP of Investor Relations & Corp. Communications
  • Mr. Alex Nemiroff J.D. (Age 44)
    Gen. Counsel & Sec.
  • Ms. Kelly McCue
    Chief People Officer
  • Ms. Alyssa J. S. Wyant (Age 48)
    Chief Regulatory & Quality Officer
  • Ms. Megan T. Sniecinski (Age 41)
    Chief Bus. Officer













PRAX Stock - Frequently Asked Questions

Should I buy or sell Praxis Precision Medicines stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Praxis Precision Medicines in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRAX shares.
View PRAX analyst ratings
or view top-rated stocks.

What is Praxis Precision Medicines' stock price forecast for 2023?

4 equities research analysts have issued 1-year price targets for Praxis Precision Medicines' stock. Their PRAX share price forecasts range from $7.00 to $10.00. On average, they expect the company's share price to reach $8.50 in the next year. This suggests a possible upside of 470.5% from the stock's current price.
View analysts price targets for PRAX
or view top-rated stocks among Wall Street analysts.

How have PRAX shares performed in 2023?

Praxis Precision Medicines' stock was trading at $2.38 at the beginning of 2023. Since then, PRAX shares have decreased by 37.4% and is now trading at $1.49.
View the best growth stocks for 2023 here
.

When is Praxis Precision Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our PRAX earnings forecast
.

How were Praxis Precision Medicines' earnings last quarter?

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) posted its earnings results on Wednesday, August, 9th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.66) by $0.17. The firm had revenue of $0.78 million for the quarter.

When did Praxis Precision Medicines IPO?

(PRAX) raised $126 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO and Blackstone Capital Markets was co-manager.

What is Praxis Precision Medicines' stock symbol?

Praxis Precision Medicines trades on the NASDAQ under the ticker symbol "PRAX."

Who are Praxis Precision Medicines' major shareholders?

Praxis Precision Medicines' stock is owned by many different retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (16.46%), Cormorant Asset Management LP (14.82%), Sphera Funds Management LTD. (13.68%), VR Adviser LLC (8.28%), Silverarc Capital Management LLC (5.42%) and Acadian Asset Management LLC (2.41%). Insiders that own company stock include Alex Nemiroff, Dean J Mitchell, Lauren Mastrocola, Marcio Souza, Parallel Master Fund LP Bsof and Timothy Edwin Kelly.
View institutional ownership trends
.

How do I buy shares of Praxis Precision Medicines?

Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Praxis Precision Medicines' stock price today?

One share of PRAX stock can currently be purchased for approximately $1.49.

How much money does Praxis Precision Medicines make?

Praxis Precision Medicines (NASDAQ:PRAX) has a market capitalization of $191.52 million. The company earns $-214,030,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis.

How many employees does Praxis Precision Medicines have?

The company employs 109 workers across the globe.

How can I contact Praxis Precision Medicines?

Praxis Precision Medicines' mailing address is 101 MAIN STREET #1210, CAMBRIDGE MA, 02142. The official website for the company is www.praxismedicines.com. The company can be reached via phone at 617-300-8460 or via email at investors@praxismedicines.com.

This page (NASDAQ:PRAX) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -